quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

How Investors Are Reacting To Salesforce (CRM) After Bank of America Flags AI Monetization Challenges

View original at finance.yahoo.com
“Salesforce's narrative projects $51.9 billion revenue and $10.3 billion earnings by 2028.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce faces a structural reset as AI reshapes its core CRM and agentic offerings.

    60% confidence
  • The near-term focus for Salesforce is squarely on whether AI features can be priced and adopted fast enough to offset slowing CRM growth.

    60% confidence
  • The most optimistic analysts project Salesforce revenues near $58.9 billion and earnings around $11.6 billion by 2029, expecting AI-driven workflows to lock customers in more tightly.

    60% confidence
  • Salesforce may be shifting from a high-growth story to a mature cash generator.

    60% confidence
  • Salesforce's consensus forecasts imply a fair value of $317.21, representing 77% upside to its current market price.

    60% confidence
  • Salesforce's narrative projects $51.9 billion in revenue and $10.3 billion in earnings by 2028, requiring 9.6% annual revenue growth.

    60% confidence
  • Salesforce's earnings need to grow approximately $3.6 billion from the current $6.7 billion to reach the 2028 target of $10.3 billion.

    60% confidence
  • Salesforce's AI monetization must not erode the existing seat-based CRM model; convincing investors on this is the biggest near-term swing factor.

    60% confidence

Data points we hold from this source

Salesforce · net income6.7 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
How Investors Are Reacting To Salesforce (CRM) After Bank of America Flags AI Monetization Challenges — Source | Via News | pt.VIA.NEWS